[
    [
        {
            "time": "2021-01-15",
            "original_text": "Belgium sees large initial shortfall of AstraZeneca vaccine",
            "features": {
                "keywords": [
                    "shortfall",
                    "AstraZeneca",
                    "vaccine"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-20",
            "original_text": "N.Y. Vaccine Shortage Eases; California Cases Slow: Virus Update",
            "features": {
                "keywords": [
                    "vaccine",
                    "shortage",
                    "eases",
                    "cases",
                    "slow"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-25",
            "original_text": "What Does 2021 Hold for BioNTech Stock?",
            "features": {
                "keywords": [
                    "BioNTech",
                    "stock",
                    "2021"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-05",
            "original_text": "Italy to rethink vaccine rollout if supply problems persist",
            "features": {
                "keywords": [
                    "Italy",
                    "vaccine",
                    "rollout",
                    "supply",
                    "problems"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-10",
            "original_text": "Here Are the Biggest Hurdles for COVID Vaccinations",
            "features": {
                "keywords": [
                    "hurdles",
                    "COVID",
                    "vaccinations"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-15",
            "original_text": "French health body recommends delaying second COVID shot to six weeks after first",
            "features": {
                "keywords": [
                    "French",
                    "health",
                    "body",
                    "recommends",
                    "delaying",
                    "second",
                    "shot"
                ],
                "sentiment_score": -0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-20",
            "original_text": "Better Buy: Gilead Sciences vs. Pfizer",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Pfizer",
                    "buy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-25",
            "original_text": "Thailand Approves AstraZeneca: Southeast Asia Vaccine Tracker",
            "features": {
                "keywords": [
                    "Thailand",
                    "approves",
                    "AstraZeneca",
                    "vaccine",
                    "tracker"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-05",
            "original_text": "It Might Not Be A Great Idea To Buy Pfizer Inc. (NYSE:PFE) For Its Next Dividend",
            "features": {
                "keywords": [
                    "Pfizer",
                    "dividend",
                    "buy",
                    "idea"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-10",
            "original_text": "MGM Stock Is Still a Good Bet, Despite Failure to Buy Entain",
            "features": {
                "keywords": [
                    "MGM",
                    "stock",
                    "good",
                    "bet",
                    "failure",
                    "Entain"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "entertainment",
                    "gaming"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]